Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

blonca9
May 6, 2024
1 min read

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell type. The company is now using this to create cells for research purposes and as therapeutics.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight